LH LONGEVITY HEALTHCARE FUND

Inception Date

March 26, 2026

Benchmark

100% of the Master Fund’s performance, adjusted as follows: 80% adjusted for the cost of foreign exchange hedging; and 20% adjusted for the exchange rate to calculate returns in Thai Baht (THB) as of the performance calculation date.

Fund Size

61 M

Fund Manager

Pornphen Chuleeprasert Benjabhorn Lertsethasart

FX Hedging

No

Dividend Policy

None

Investment Policy

The Fund has a policy to invest in units of a foreign mutual fund (the “Master Fund”) with an equity investment strategy. The Fund will invest, on average over an accounting year, not less than 80% of its net asset value (NAV) in units of the Master Fund. The Fund will invest in Tema Oncology ETF (the “Master Fund”), which is denominated in U.S. Dollars (USD) and listed exclusively on the NASDAQ Stock Market. The Master Fund is established under the laws of the United States of America (USA). Tema ETFs LLC (the “Adviser”) serves as the primary investment adviser to the Master Fund and is responsible for providing investment advisory services, including oversight and monitoring of portfolio transactions, as well as regular reviews of the performance of the sub-investment adviser. NEOS Investment Management, LLC (the “Sub-Adviser”) acts as the sub-investment adviser and is responsible for implementing the investment strategy of the Master Fund in accordance with instructions and guidelines provided by the Adviser. The Sub-Adviser is also responsible for executing securities transactions and selecting broker-dealers, subject to the supervision of the Adviser pursuant to the Sub-Advisory Agreement. The Fund will invest in units of the Master Fund at an average allocation of not less than 80% of the Fund’s NAV over an accounting year. The Master Fund is actively managed and seeks to achieve long-term capital growth by investing in companies operating within the oncology industry, including pharmaceutical, biotechnology, therapeutic technology, and cancer diagnostics companies. The Master Fund will invest at least 80% of its net assets, plus any borrowings for investment purposes (if any), in publicly listed companies that derive at least 50% of their revenues from oncology-related businesses. The Fund will invest overseas and, as a result, will maintain a net exposure to foreign investment risk averaging not less than 80% of its NAV during an accounting year, or such other proportion as may be prescribed by the Office of the Securities and Exchange Commission of Thailand (SEC Thailand). For the remaining portion of the portfolio, the Fund may invest in units of leveraged ETFs and/or inverse ETFs for portfolio management purposes. The Fund may also invest, both domestically and internationally, in deposit-like instruments, deposits, debt securities, equity securities, hybrid securities, warrants, as well as other securities, assets, or alternative income-generating investments as specified in the Fund Scheme and/or as permitted or approved by the SEC Thailand.Provide your feedback on BizChat